MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
MyoKardia - Review Phase 3 EXPLORER-HCM Trial Design (Replay)
May 21, 2018 at 8:30 a.m. ET
Recent Press Releases
05/21/18MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
NASDAQ GS | MYOK (Common Stock)
$47.70 - 0.55
05/25/184:01 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.